Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SRZN
stocks logo

SRZN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-1.303
-85.68%
0.00
-100%
-1.450
-80.48%
--
--
-1.447
-156.73%
Estimates Revision
The market is revising Downward the revenue expectations for Surrozen, Inc. (SRZN) for FY2025, with the revenue forecasts being adjusted by -12.19% over the past three months. During the same period, the stock price has changed by 49.43%.
Revenue Estimates for FY2025
Revise Downward
down Image
-12.19%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+13.69%
In Past 3 Month
Stock Price
Go Up
up Image
+49.43%
In Past 3 Month
Wall Street analysts forecast SRZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRZN is 36.67 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast SRZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRZN is 36.67 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.230
sliders
Low
32.00
Averages
36.67
High
42.00
Current: 18.230
sliders
Low
32.00
Averages
36.67
High
42.00
LifeSci Capital
Patrick Dolezal
Outperform
initiated
$36
2025-11-13
Reason
LifeSci Capital
Patrick Dolezal
Price Target
$36
2025-11-13
initiated
Outperform
Reason
LifeSci Capital analyst Patrick Dolezal initiated coverage of Surrozen with an Outperform rating and $36 price target.
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$32
2025-04-02
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$32
2025-04-02
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Initiates
$32
2025-01-30
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$32
2025-01-30
Initiates
Strong Buy
Reason
Guggenheim
Yatin Suneja
Hold
to
Strong Buy
Upgrades
$45
2025-01-03
Reason
Guggenheim
Yatin Suneja
Price Target
$45
2025-01-03
Upgrades
Hold
to
Strong Buy
Reason
Guggenheim analyst Yatin Suneja upgraded Surrozen to Buy from Neutral with a $45 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Surrozen Inc (SRZN.O) is -2.88, compared to its 5-year average forward P/E of -1.84. For a more detailed relative valuation and DCF analysis to assess Surrozen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.84
Current PE
-2.88
Overvalued PE
-0.34
Undervalued PE
-3.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.29
Undervalued EV/EBITDA
-2.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.11
Current PS
0.00
Overvalued PS
74.69
Undervalued PS
-40.47
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SRZN News & Events

Events Timeline

(ET)
2025-11-07
16:18:49
Surrozen appoints Andrew Maleki as Chief Financial Officer
select
2025-05-14 (ET)
2025-05-14
08:35:58
Surrozen granted patent from USPTO directed to antibody-based molecules
select
2025-04-23 (ET)
2025-04-23
16:21:04
Surrozen files to sell 5.21M shares of common stock for holders
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
08-09NASDAQ.COM
Surrozen Reports Q2 Profit on Gains

  • Financial Performance: Surrozen reported a GAAP EPS of $2.55 for Q2 2025, significantly exceeding expectations due to non-cash gains, while also achieving a net income of $39.7 million despite ongoing operating losses and increased research expenses.

  • Pipeline and Strategy: The company is advancing its ophthalmology drug candidates SZN-8141 and SZN-8143 targeting retinal diseases, with plans to submit an IND application in 2026, while relying on strategic partnerships for revenue and expertise amidst challenges in clinical trial timelines and cash management.

[object Object]
Preview
9.5
08-09Newsfilter
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

  • Leadership Changes and Advisory Board Formation: Surrozen has appointed Daniel Chao, M.D., Ph.D., as Vice President of Clinical Development and established a Clinical Advisory Board of leading retinal specialists to enhance its ophthalmology pipeline focused on severe eye diseases.

  • Financial Performance and Pipeline Progress: The company reported a net income of $39.7 million for Q2 2025, attributed to increased research service revenue and a strong cash position, while advancing its lead candidates SZN-8141 and SZN-8143 towards clinical trials.

[object Object]
Preview
9.0
05-14Newsfilter
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

  • Patent Issuance: Surrozen, Inc. has been granted U.S. Patent No. 12,297,278 for its SWAP™ technology, which covers novel tetravalent Wnt surrogate molecules designed to enhance Wnt pathway signaling for therapeutic applications.

  • Product Development: The company is advancing multiple product candidates targeting retinal diseases, including SZN-8141 and SZN-8143, which combine Frizzled agonism and VEGF antagonism to potentially improve treatment outcomes over existing therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Surrozen Inc (SRZN) stock price today?

The current price of SRZN is 18.23 USD — it has increased 15.75 % in the last trading day.

arrow icon

What is Surrozen Inc (SRZN)'s business?

Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.

arrow icon

What is the price predicton of SRZN Stock?

Wall Street analysts forecast SRZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRZN is 36.67 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Surrozen Inc (SRZN)'s revenue for the last quarter?

Surrozen Inc revenue for the last quarter amounts to 983.00K USD, decreased -90.17 % YoY.

arrow icon

What is Surrozen Inc (SRZN)'s earnings per share (EPS) for the last quarter?

Surrozen Inc. EPS for the last quarter amounts to -8.36 USD, increased 1800.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Surrozen Inc (SRZN)'s fundamentals?

The market is revising Downward the revenue expectations for Surrozen, Inc. (SRZN) for FY2025, with the revenue forecasts being adjusted by -12.19% over the past three months. During the same period, the stock price has changed by 49.43%.
arrow icon

How many employees does Surrozen Inc (SRZN). have?

Surrozen Inc (SRZN) has 40 emplpoyees as of December 05 2025.

arrow icon

What is Surrozen Inc (SRZN) market cap?

Today SRZN has the market capitalization of 156.26M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free